Benzinga | Dec 8, 2021 05:48AM EST

Adicet Bio Priced 6.25M Share Public Offering of Common Stock @$14/Share

Adicet Bio, Inc. ("Adicet") (NASDAQ:ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $87.5 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Adicet. The offering is expected to close on or about December 10, 2021, subject to the satisfaction of customary closing conditions.

Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. Truist Securities is acting as passive book-runner for the offering. BTIG, H.C. Wainwright & Co. and JonesTrading are acting as co-managers for the offering.